Citadel Advisors
ZVRA icon

Citadel Advisors’s Zevra Therapeutics ZVRA Stock Holding History

Citadel Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$391K Sell
42,000
-14,000
-25% -$126K ﹤0.01% 9862
2025
Q4 		$502K Sell
56,000
-63,600
-53% -$601K ﹤0.01% 9009
2025
Q3 		$1.14M Buy
+119,600
New +$1.2M ﹤0.01% 7254
2025
Q2 		– Sell
-3,900
Closed -$29.2K – 15463
2025
Q1 		$29.2K Sell
3,900
-20,200
-84% -$161K ﹤0.01% 12849
2024
Q4 		$201K Sell
24,100
-18,900
-44% -$161K ﹤0.01% 10453
2024
Q3 		$298K Buy
43,000
+25,200
+142% +$171K ﹤0.01% 9343
2024
Q2 		$87.2K Buy
17,800
+2,000
+13% +$9.48K ﹤0.01% 11103
2024
Q1 		$91.6K Sell
15,800
-23,900
-60% -$147K ﹤0.01% 11475
2023
Q4 		$260K Buy
39,700
+8,200
+26% +$38.4K ﹤0.01% 9442
2023
Q3 		$152K Sell
31,500
-16,000
-34% -$79.9K ﹤0.01% 10334
2023
Q2 		$242K Sell
47,500
-43,800
-48% -$236K ﹤0.01% 9475
2023
Q1 		$502K Buy
91,300
+15,400
+20% +$81.5K ﹤0.01% 8300
2022
Q4 		$348K Sell
75,900
-151,400
-67% -$769K ﹤0.01% 8988
2022
Q3 		$1.42M Sell
227,300
-23,900
-10% -$135K ﹤0.01% 6264
2022
Q2 		$1.12M Sell
251,200
-1,700
-0.7% -$7.75K ﹤0.01% 6767
2022
Q1 		$1.27M Sell
252,900
-153,100
-38% -$974K ﹤0.01% 7142
2021
Q4 		$3.54M Buy
406,000
+265,400
+189% +$2.37M ﹤0.01% 5004
2021
Q3 		$1.31M Buy
140,600
+87,400
+164% +$881K ﹤0.01% 7438
2021
Q2 		$682K Sell
53,200
-22,900
-30% -$246K ﹤0.01% 9297
2021
Q1 		$700K Buy
+76,100
New +$664K ﹤0.01% 8946

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Citadel Advisors's ZVRA Position: Q1 2026 in Review

Citadel Advisors reduced its Zevra Therapeutics (ZVRA) stake by 26% in Q1 2026, selling an estimated $1.95M and leaving 626,699 shares worth $5.84M. The position accounts for ﹤0.01% of the portfolio, ranked #4088.

Citadel Advisors first reported a position in ZVRA in Q4 2019 and has held it in 19 quarters since. The position peaked at $7.55M in Q4 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Citadel Advisors held 626,699 shares of Zevra Therapeutics worth $5.84M as of Q1 2026.
  • Citadel Advisors sold 216,155 Zevra Therapeutics shares in Q1 2026, an estimated $1.95M.
  • Zevra Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4088 holding.
  • Citadel Advisors first reported a position in Zevra Therapeutics in Q4 2019 and has held it in 19 quarters since.
  • Citadel Advisors's Zevra Therapeutics position peaked at $7.55M in Q4 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.